CervoMed, Inc. (CRVO)
8.42
-0.21
(-2.43%)
USD |
NASDAQ |
Dec 10, 12:22
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 77.91M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -15.80% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 12.06 |
| Price to Book Value | 2.995 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.76% |
Profile
| CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA. |
| URL | http://www.cervomed.com |
| Investor Relations URL | https://ir.cervomed.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 19, 2026 (est.) |
| Last Earnings Release | Nov. 11, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA. |
| URL | http://www.cervomed.com |
| Investor Relations URL | https://ir.cervomed.com/ |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 19, 2026 (est.) |
| Last Earnings Release | Nov. 11, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |